Technical Analysis for XRTX - Xortx Therapeutics Inc

Grade Last Price % Change Price Change
A 4.100 3.80% 0.150
XRTX closed up 6.76 percent on Tuesday, November 28, 2023, on 10 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 3.80%
180 Bullish Setup Bullish Swing Setup 3.80%
Wide Bands Range Expansion 3.80%
Overbought Stochastic Strength 3.80%
Narrow Range Bar Range Contraction 10.81%
Wide Bands Range Expansion 10.81%
Overbought Stochastic Strength 10.81%
Wide Bands Range Expansion 9.33%
Overbought Stochastic Strength 9.33%
1,2,3 Pullback Bullish Bullish Swing Setup 13.89%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Bullish 180 Entry 22 minutes ago
Rose Above Previous Day's High 22 minutes ago
Up 3% 22 minutes ago
Up 2% 22 minutes ago
Up 1% 22 minutes ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xortx Therapeutics Inc Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease

Is XRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.25
52 Week Low 0.33
Average Volume 37,251
200-Day Moving Average 0.947
50-Day Moving Average 1.236
20-Day Moving Average 2.192
10-Day Moving Average 3.612
Average True Range 0.341
RSI (14) 78.49
ADX 49.29
+DI 54.730
-DI 7.476
Chandelier Exit (Long, 3 ATRs) 3.228
Chandelier Exit (Short, 3 ATRs) 1.392
Upper Bollinger Bands 5.348
Lower Bollinger Band -0.965
Percent B (%b) 0.78
BandWidth 288.037
MACD Line 0.870
MACD Signal Line 0.719
MACD Histogram 0.151
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.355
Resistance 3 (R3) 4.317 4.143 4.288
Resistance 2 (R2) 4.143 4.040 4.163 4.265
Resistance 1 (R1) 4.047 3.976 4.095 4.085 4.242
Pivot Point 3.873 3.873 3.898 3.893 3.873
Support 1 (S1) 3.777 3.770 3.825 3.815 3.658
Support 2 (S2) 3.603 3.706 3.623 3.635
Support 3 (S3) 3.507 3.603 3.613
Support 4 (S4) 3.545